Convatec Group (CTEC) Stock Overview
Engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
CTEC Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Convatec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.20 |
| 52 Week High | UK£2.67 |
| 52 Week Low | UK£1.93 |
| Beta | 0.76 |
| 1 Month Change | 12.67% |
| 3 Month Change | -0.18% |
| 1 Year Change | -17.26% |
| 3 Year Change | 9.36% |
| 5 Year Change | -13.13% |
| Change since IPO | -2.40% |
Recent News & Updates
CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential
Convatec Group's analyst price targets have been trimmed, with recent moves such as Citi cutting its view to £2.30 from £2.50 and JPMorgan to £2.94 from £3.07, highlighting a more cautious stance even as analysts point to steady assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. Analyst Commentary Recent research on Convatec Group points to a mixed but engaged view from the Street, with some analysts trimming price targets while others make supportive adjustments that reflect differing opinions on valuation, execution and growth potential.CTEC: Advanced Wound Care Pipeline And Ostomy Launch Will Support Future Rerating Potential
The analyst price target for Convatec Group has been revised downward to reflect recent Street research changes, including reductions to a range of approximately £2.30 to £2.94, along with updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Convatec Group points to a more cautious stance on valuation, even as some analysts maintain a constructive view on the company’s execution and earnings potential.CTEC: Renewed Coverage And Ostomy Launch Will Support Future Rerating Potential
Convatec Group's updated analyst price target edges higher to about £3.04 from £3.03, with analysts pointing to modestly stronger revenue growth and profit margin assumptions, partially offset by a lower future P/E multiple and recent mixed target moves from major banks. Analyst Commentary Recent Street research on Convatec Group points to a mixed but generally constructive stance, with small price target tweaks and rating reiterations helping frame how analysts are thinking about valuation, execution and growth expectations.Recent updates
CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential
Convatec Group's analyst price targets have been trimmed, with recent moves such as Citi cutting its view to £2.30 from £2.50 and JPMorgan to £2.94 from £3.07, highlighting a more cautious stance even as analysts point to steady assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. Analyst Commentary Recent research on Convatec Group points to a mixed but engaged view from the Street, with some analysts trimming price targets while others make supportive adjustments that reflect differing opinions on valuation, execution and growth potential.CTEC: Advanced Wound Care Pipeline And Ostomy Launch Will Support Future Rerating Potential
The analyst price target for Convatec Group has been revised downward to reflect recent Street research changes, including reductions to a range of approximately £2.30 to £2.94, along with updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Convatec Group points to a more cautious stance on valuation, even as some analysts maintain a constructive view on the company’s execution and earnings potential.CTEC: Renewed Coverage And Ostomy Launch Will Support Future Rerating Potential
Convatec Group's updated analyst price target edges higher to about £3.04 from £3.03, with analysts pointing to modestly stronger revenue growth and profit margin assumptions, partially offset by a lower future P/E multiple and recent mixed target moves from major banks. Analyst Commentary Recent Street research on Convatec Group points to a mixed but generally constructive stance, with small price target tweaks and rating reiterations helping frame how analysts are thinking about valuation, execution and growth expectations.CTEC: Novo Exit And Renewed Coverage Will Support Future Rerating Potential
Narrative Update Analysts have nudged their fair value estimate for Convatec Group slightly higher to £3.03 from £3.02, citing resumed positive coverage and a higher price target from recent Street research, while also updating assumptions on the discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent Street research has brought fresh attention to Convatec Group, with coverage resuming and the price target adjusted in line with updated assumptions on growth, profitability and valuation multiples.CTEC: Novo Exit And New Leadership Will Support Rerating Potential
Analysts have inched their fair value estimate for Convatec Group slightly lower to about £3.02 per share from roughly £3.04, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples following recent price target moves, including a 10 GBp increase cited in Street research. Analyst Commentary Street research pointing to a 10 GBp uplift in the price target has prompted a modest reassessment of assumptions behind the updated fair value, but opinions are still split on how much upside remains from current levels.Convatec Group PLC's (LON:CTEC) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights The projected fair value for Convatec Group is UK£3.22 based on 2 Stage Free Cash Flow to Equity Current...Convatec Group's (LON:CTEC) Returns On Capital Are Heading Higher
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Here's Why ConvaTec Group (LON:CTEC) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...ConvaTec Group PLC's (LON:CTEC) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 28.4x ConvaTec Group PLC ( LON:CTEC ) may be sending very bearish signals...Global Demographic Shifts And Emerging Markets Will Create Enduring Opportunity
Analysts have modestly reduced their price target for ConvaTec Group, reflecting a decline from £3.05 to £3.04 per share as they factor in revised sector outlooks and modest adjustments to growth expectations. Analyst Commentary Recent analyst revisions provide a mixed view of ConvaTec Group's prospects, with both optimistic and cautious signals emerging from updated research.Returns On Capital Are Showing Encouraging Signs At ConvaTec Group (LON:CTEC)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Robust Product Pipeline And Automation Investments Will Drive Future Market Expansion
ConvaTec's new product pipeline and market share growth in chronic care categories align well for sustained revenue expansion and innovative market leadership.Shareholder Returns
| CTEC | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 3.7% | -1.4% | 0.2% |
| 1Y | -17.3% | -4.7% | 18.1% |
Return vs Industry: CTEC underperformed the UK Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: CTEC underperformed the UK Market which returned 18.1% over the past year.
Price Volatility
| CTEC volatility | |
|---|---|
| CTEC Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: CTEC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: CTEC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,910 | Jonny Mason | www.convatecgroup.com |
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma.
Convatec Group PLC Fundamentals Summary
| CTEC fundamental statistics | |
|---|---|
| Market cap | UK£4.29b |
| Earnings (TTM) | UK£131.12m |
| Revenue (TTM) | UK£1.83b |
Is CTEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTEC income statement (TTM) | |
|---|---|
| Revenue | US$2.44b |
| Cost of Revenue | US$1.07b |
| Gross Profit | US$1.37b |
| Other Expenses | US$1.20b |
| Earnings | US$175.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 56.25% |
| Net Profit Margin | 7.18% |
| Debt/Equity Ratio | 92.1% |
How did CTEC perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 23:03 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Convatec Group PLC is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Samuel England | Berenberg |
| Susannah Ludwig | Bernstein |